For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

Clinical Coverage

Additional Drug Updates

Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: Treatment Algorithm for Seronegative Patients

23h ago|4 min read|By Dr. Vikram Patel
Neurology

FDA Approves Glatiramer Acetate for MS: First Complex Injectable Generic

23h ago|4 min read|By Dr. Vikram Patel
Endocrinology

FDA Proposes Exclusion of Semaglutide and Tirzepatide from 503B Bulks List: Impact on Compounding Access

23h ago|4 min read|By Dr. Amit Desai
Endocrinology

FDA Approves Langlara for Diabetes: Interchangeable Biosimilar to Lantus

Jun 11|4 min read|By Dr. Amit Desai
Pediatrics

FDA Approves Nirsevimab for RSV Prevention: Key Findings from MELODY Trial

Jun 11|5 min read|By Dr. Sneha Rao
Neurology

FDA Approves Zycubo for Menkes Disease: First Pediatric Copper Replacement Therapy

Jun 11|4 min read|By Dr. Vikram Patel
Neurology

FDA Approves Tyruko for MS: First Biosimilar to Natalizumab

Jun 11|4 min read|By Dr. Vikram Patel
Pulmonology

FDA Approves Tezepelumab for Severe Asthma: 52% Exacerbation Reduction in NAVIGATOR Trial

Jun 11|4 min read|By Dr. Nikhil Chatterjee
Oncology

FDA Approves Mirdametinib for Neurofibromatosis Type 1: 41% ORR in ReNeu Trial

Jun 11|5 min read|By Dr. Meera Pillai
Infectious Disease

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

Jun 11|4 min read|By Dr. Simran Kohli
Rare Disease

FDA Approves Kygevvi for Thymidine Kinase 2 Deficiency: 9.6 Years Mean Survival

Jun 11|4 min read|By Editorial Team
Cardiology

FDA Approves Empagliflozin for HFpEF: 21% Heart Failure Hospitalization Reduction in EMPEROR-Preserved Trial

Jun 10|4 min read|By Dr. Arjun Sharma
Nephrology

FDA Approves Finerenone for CKD: 18% Risk Reduction in FIDELIO-DKD Trial

Jun 10|4 min read|By Dr. Praveen Singh
Hematology

FDA Approves Yartemlea for TA-TMA: First Treatment for Stem Cell Transplant Complication

Jun 10|4 min read|By Dr. Shruti Pandey
Oncology

FDA Approves Telisotuzumab Vedotin for NSCLC: 35% ORR in LUMINOSITY Trial

Jun 9|4 min read|By Dr. Meera Pillai
Oncology

FDA Approves Olaparib for BRCA-Mutated mCRPC: 24% rPFS Improvement in PROpel Trial

Jun 9|4 min read|By Dr. Rahul Verma
Dermatology

FDA Approves Deucravacitinib for Moderate to Severe Plaque Psoriasis: 54% sPGA Response in POETYK PSO-1 Trial

Jun 9|4 min read|By Dr. Divya Agarwal
Infectious Disease

FDA Approves Rezafungin for Invasive Candidiasis: 70.2% Efficacy in ReSTORE Trial

Jun 9|4 min read|By Dr. Simran Kohli
Oncology

FDA Approves Pembrolizumab for HER2-Positive Gastric Cancer: 10.9 Months PFS in KEYNOTE-811 Trial

Jun 9|4 min read|By Dr. Meera Pillai
Endocrinology

Rybelsus vs Orforglipron: Head-to-Head HbA1c Reduction and Weight Loss Without Food Restrictions

Jun 9|4 min read|By Dr. Amit Desai
Cardiology

FDA Approves Semaglutide for HFpEF: 13.3% KCCQ Score Improvement in STEP-HFpEF Trial

Jun 9|4 min read|By Dr. Kavya Sharma
Dermatology

FDA Approves Roflumilast for Pediatric Plaque Psoriasis: 42% IGA Success in Children 2 to 5 Years

Jun 9|4 min read|By Dr. Divya Agarwal
Oncology

Sonrotoclax Shows 65.5% ORR in BRUIN MCL-321 Trial for MCL

Jun 9|4 min read|By Dr. Meera Pillai